Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cost-Cutting Sequel Yields Little Surprise: PhRMA Supports Efficient Medication Use, More Drug Development, Expanded Access

This article was originally published in The Pink Sheet Daily

Executive Summary

Following up on their pledge to help reduce growing health costs, PhRMA, other health groups provide more specifics to President Obama.

You may also be interested in...



PhRMA, Others Look For Savings In Reduced Drug Interactions

Reducing the instances of adverse events related to drug-drug interactions is among the options to reduce health care spending presented by both the Pharmaceutical Research and Manufacturers of America and the American Medical Association

PhRMA, Others Look For Savings In Reduced Drug Interactions

Reducing the instances of adverse events related to drug-drug interactions is among the options to reduce health care spending presented by both the Pharmaceutical Research and Manufacturers of America and the American Medical Association

Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine

As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel